Kubota Pharmaceutical Holdings Co. Ltd. (4596) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Wakamoto Pharmaceutical Co., Ltd.

Perseus Proteomics, Inc.

Kainos Laboratories, Inc.

Solasia Pharma KK

Nippon Chemiphar Co., Ltd.

Pharmarise Holdings Corp.

Kubota Pharmaceutical Holdings Co. Ltd.

D. Western Therapeutics Institute, Inc.

Renascience, Inc.

BrightPath Biotherapeutics Co., Ltd.

Delta-Fly Pharma, Inc.

Why is Kubota Pharmaceutical Holdings Co. Ltd. ?

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE
NET SALES(Q) Lowest at JPY 3.1 MM
OPERATING PROFIT MARGIN(Q) Lowest at -7,752.26 %
RAW MATERIAL COST(Y) Grown by 479.56% (YoY)

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 108.00%, its profits have risen by 6.7%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Kubota Pharmaceutical Holdings Co. Ltd. for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Kubota Pharmaceutical Holdings Co. Ltd.

108.0%

0.33

141.75%

Japan Nikkei 225

36.73%

1.30

28.24%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

97.96%

EBIT Growth (5y)

10.62%

EBIT to Interest (avg)

-173.86

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.03

Sales to Capital Employed (avg)

0.02

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.08

EV to EBIT

-1.13

EV to EBITDA

-1.18

EV to Capital Employed

-35.31

EV to Sales

43.33

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-98.40%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company

OPERATING CASH FLOW(Y)

Highest at JPY -581.14 MM

NET PROFIT(HY)

Higher at JPY -444.31 MM

ROCE(HY)

Highest at -42.22%

DEBT-EQUITY RATIO (HY)

Lowest at -104.55 %

-16What is not working for the Company

NET SALES(Q)

Lowest at JPY 3.1 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -7,752.26 %

RAW MATERIAL COST(Y)

Grown by 479.56% (YoY

Here's what is working for Kubota Pharmaceutical Holdings Co. Ltd.

Operating Cash Flow

Highest at JPY -581.14 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (JPY MM)

Net Profit

Higher at JPY -444.31 MM

than preceding 12 month period ended Dec 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (JPY MM)

Debt-Equity Ratio

Lowest at -104.55 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Kubota Pharmaceutical Holdings Co. Ltd.

Net Sales

At JPY 3.1 MM has Fallen at -56.13%

over average net sales of the previous four periods of JPY 7.07 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (JPY MM)

Net Sales

Lowest at JPY 3.1 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term sales trend is very negative

Net Sales (JPY MM)

Operating Profit Margin

Lowest at -7,752.26 % and Fallen

In each period in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Raw Material Cost

Grown by 479.56% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales